Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 9/20 | 0.47 |
| ▸ | NOS1 | P29475 | 8/20 | 0.47 |
| ▸ | NOS3 | P29474 | 6/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL323015 | 1.00 | OTC (0.49) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL29678739 | 0.92 | OTC (0.48) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL5544125 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL1821002 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL1675351 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL5544129 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL9754275 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL5312506 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL2787541 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL2397458 | 0.92 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930666-B1 | ORAL CARE PRODUCT | COLGATE PALMOLIVE CO (US) | 2026-05-27 | — | — | EP | claimed |
| US-20250213449-A1 | Oral Care Product And Methods Of Use And Manufacture Thereof | COLGATE-PALMOLIVE COMPANY (US) | 2025-07-03 | — | — | US | claimed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3930666-A1 | ORAL CARE PRODUCT | Colgate-Palmolive Company (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113543763-A | Oral care products | 高露洁-棕榄公司 | 2021-10-22 | — | — | CN | claimed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | claimed |
| WO-2020205342-A1 | ORAL CARE PRODUCT | COLGATE-PALMOLIVE COMPANY (US) | 2020-10-08 | — | — | WO | claimed |
| US-20200306159-A1 | Oral Care Product and Methods of Use and Manufacture Thereof | COLGATE-PALMOLIVE COMPANY (US) | 2020-10-01 | — | — | US | claimed |
| EP-3277086-A2 | ANTI-MICROBIAL COMPOSITION | Byotrol PLC (GB) | 2018-02-07 | — | — | EP | claimed |
| CN-107466207-A | Antimicrobial compositions | 拜奥特罗尔有限公司 | 2017-12-12 | — | — | CN | claimed |
| WO-2016156869-A2 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2016-10-06 | — | — | WO | claimed |
| EP-3930666-B1 | ORAL CARE PRODUCT | COLGATE PALMOLIVE CO (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-121287537-B | Preparation and application of anti-dandruff composition containing kuh-seng polypeptide | 广州锦同生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4340807-B1 | HAIR COLOR COMPOSITIONS FOR MITIGATING COLOR LOSS | LUBRIZOL ADVANCED MAT INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-0502007-A4 | METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE | — | 1992-11-19 | — | — | EP | disclosed |
| US-5157022-A | Administering arginine nicotinate and di- and tripeptides of arginine | BARBUL ADRIAN (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0502007-A1 | ARGININE NICOTINATE FOR REDUCING BLOOD CHOLESTEROL | BARBUL, Adrian (US) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007188-A1 | METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE | BARBUL ADRIAN (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | OTC 2611/4885NOS2 2332/4885NOS1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.